FDA Approves Feasibility Study with SeaStar Medical’s Selective Cytopheretic Device in Adults with Cardiorenal Syndrome
Study to be conducted under $3.6 million NIH grant DENVER, Jan. 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), ...
thecardiologyadvisor.com19h
Microaxial Ventricular Assist Devices: Fewer Deaths Among High Volume Centers
Hospitals with a higher volume of percutaneous microaxial ventricular assist device implantation in the US have fewer deaths among cardiogenic shock patients.
SeaStar Medical says FDA approves feasibility study with SCD-ADULT
SeaStar Medical (ICU) announced that the U.S. FDA has approved an investigational device exemption application to evaluate the safety and ...
Future Market Insights21h
Cardiac Assist Devices Industry to Reach USD 2.48 Billion by 2033, Growing at a 6.1% CAGR
The global cardiac assist devices market is set to grow significantly over the next decade, with its valuation projected to ...